Cargando…
Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory?
Background/Aims: Controversy exists regarding 3- or 4 drug antituberculosis therapy (conventional ATT) in uveitis patients having latent tuberculosis (LTB), especially while initiating therapy with corticosteroids and/or other immunosuppressants. Methods: We performed a monocentral retrospective ana...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105017/ https://www.ncbi.nlm.nih.gov/pubmed/35566544 http://dx.doi.org/10.3390/jcm11092419 |
_version_ | 1784707936866533376 |
---|---|
author | Bigdon, Eileen Steinhorst, Nils Alexander Weissleder, Stephanie Durchkiv, Vasyl Stübiger, Nicole |
author_facet | Bigdon, Eileen Steinhorst, Nils Alexander Weissleder, Stephanie Durchkiv, Vasyl Stübiger, Nicole |
author_sort | Bigdon, Eileen |
collection | PubMed |
description | Background/Aims: Controversy exists regarding 3- or 4 drug antituberculosis therapy (conventional ATT) in uveitis patients having latent tuberculosis (LTB), especially while initiating therapy with corticosteroids and/or other immunosuppressants. Methods: We performed a monocentral retrospective analysis of posterior uveitis patients with latent TB. Latent TB was diagnosed, in case of a positive QuantiFERON(®)-TB-Gold test and normal chest imaging, after ruling out other causes of infectious and noninfectious uveitis. Patients with active TB were excluded. From 2016 to 2020 we included 17 patients. Ophthalmological evaluation consisted of Best corrected visual acuity (BCVA), slit lamp examination, fundoscopy, OCT, and fluorescein- and indocyaningreen- angiography before and at months 3, 6, 12, 24, and the last follow-up after treatment. Results: Initially, all patients had active posterior uveitis with occlusive (n = 5 patients) and nonocclusive retinal vasculitis (n = 12 patients). Mean follow up was 28 ± 15 months. Therapy was started with systemic corticosteroids (mean prednisolone equivalent 71.3 mg/d) and already after 3 months it could be tapered to a mean maintenance dosage of 8.63 mg/d. Additional immunosuppressive treatment with cs- or bDMARDs was initiated in 14 patients (82%) due to recurrences of uveitis while tapering the corticosteroids <10 mg per/day or because of severe inflammation at the initial visit. While being on immunosuppression, best corrected visual acuity increased from 0.56 logMAR to 0.32 logMAR during follow-up and only three patients had one uveitis relapse, which was followed by switch of immunosuppressive treatment. As recommended, TB prophylaxis with 300 mg/d isoniazid was administered in 11 patients for at least 9 months while being on TNF-alpha-blocking agents. No patient developed active tuberculosis during immunosuppressive therapy. Conclusion: Mainly conventional ATT is strongly recommended—as monotherapy or in combination with immunosuppressives—for effective treatment in patients with uveitis due to latent TB. Although in our patient group no conventional ATT was initiated, immunosuppression alone occurred as an efficient treatment. Nevertheless, due to possible activation of TB, isoniazid prophylaxis is mandatory in latent TB patients while being on TNF-alpha blocking agents. |
format | Online Article Text |
id | pubmed-9105017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91050172022-05-14 Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory? Bigdon, Eileen Steinhorst, Nils Alexander Weissleder, Stephanie Durchkiv, Vasyl Stübiger, Nicole J Clin Med Article Background/Aims: Controversy exists regarding 3- or 4 drug antituberculosis therapy (conventional ATT) in uveitis patients having latent tuberculosis (LTB), especially while initiating therapy with corticosteroids and/or other immunosuppressants. Methods: We performed a monocentral retrospective analysis of posterior uveitis patients with latent TB. Latent TB was diagnosed, in case of a positive QuantiFERON(®)-TB-Gold test and normal chest imaging, after ruling out other causes of infectious and noninfectious uveitis. Patients with active TB were excluded. From 2016 to 2020 we included 17 patients. Ophthalmological evaluation consisted of Best corrected visual acuity (BCVA), slit lamp examination, fundoscopy, OCT, and fluorescein- and indocyaningreen- angiography before and at months 3, 6, 12, 24, and the last follow-up after treatment. Results: Initially, all patients had active posterior uveitis with occlusive (n = 5 patients) and nonocclusive retinal vasculitis (n = 12 patients). Mean follow up was 28 ± 15 months. Therapy was started with systemic corticosteroids (mean prednisolone equivalent 71.3 mg/d) and already after 3 months it could be tapered to a mean maintenance dosage of 8.63 mg/d. Additional immunosuppressive treatment with cs- or bDMARDs was initiated in 14 patients (82%) due to recurrences of uveitis while tapering the corticosteroids <10 mg per/day or because of severe inflammation at the initial visit. While being on immunosuppression, best corrected visual acuity increased from 0.56 logMAR to 0.32 logMAR during follow-up and only three patients had one uveitis relapse, which was followed by switch of immunosuppressive treatment. As recommended, TB prophylaxis with 300 mg/d isoniazid was administered in 11 patients for at least 9 months while being on TNF-alpha-blocking agents. No patient developed active tuberculosis during immunosuppressive therapy. Conclusion: Mainly conventional ATT is strongly recommended—as monotherapy or in combination with immunosuppressives—for effective treatment in patients with uveitis due to latent TB. Although in our patient group no conventional ATT was initiated, immunosuppression alone occurred as an efficient treatment. Nevertheless, due to possible activation of TB, isoniazid prophylaxis is mandatory in latent TB patients while being on TNF-alpha blocking agents. MDPI 2022-04-26 /pmc/articles/PMC9105017/ /pubmed/35566544 http://dx.doi.org/10.3390/jcm11092419 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bigdon, Eileen Steinhorst, Nils Alexander Weissleder, Stephanie Durchkiv, Vasyl Stübiger, Nicole Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory? |
title | Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory? |
title_full | Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory? |
title_fullStr | Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory? |
title_full_unstemmed | Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory? |
title_short | Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory? |
title_sort | treatment in latent tuberculosis uveitis—is immunosuppression effective or is conventional 3- or 4-drug antituberculosis therapy mandatory? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105017/ https://www.ncbi.nlm.nih.gov/pubmed/35566544 http://dx.doi.org/10.3390/jcm11092419 |
work_keys_str_mv | AT bigdoneileen treatmentinlatenttuberculosisuveitisisimmunosuppressioneffectiveorisconventional3or4drugantituberculosistherapymandatory AT steinhorstnilsalexander treatmentinlatenttuberculosisuveitisisimmunosuppressioneffectiveorisconventional3or4drugantituberculosistherapymandatory AT weisslederstephanie treatmentinlatenttuberculosisuveitisisimmunosuppressioneffectiveorisconventional3or4drugantituberculosistherapymandatory AT durchkivvasyl treatmentinlatenttuberculosisuveitisisimmunosuppressioneffectiveorisconventional3or4drugantituberculosistherapymandatory AT stubigernicole treatmentinlatenttuberculosisuveitisisimmunosuppressioneffectiveorisconventional3or4drugantituberculosistherapymandatory |